Your browser is no longer supported. Please, upgrade your browser.
Settings
CRL [NYSE]
Charles River Laboratories International, Inc.
Index- P/E39.04 EPS (ttm)7.18 Insider Own0.70% Shs Outstand49.75M Perf Week-4.22%
Market Cap14.09B Forward P/E27.04 EPS next Y10.36 Insider Trans-27.54% Shs Float48.98M Perf Month5.54%
Income364.30M PEG2.81 EPS next Q2.18 Inst Own97.00% Short Float1.35% Perf Quarter20.76%
Sales2.92B P/S4.82 EPS this Y41.90% Inst Trans0.92% Short Ratio2.14 Perf Half Y29.08%
Book/sh42.50 P/B6.59 EPS next Y12.79% ROA6.90% Target Price319.50 Perf Year73.97%
Cash/sh4.56 P/C61.41 EPS next 5Y13.87% ROE19.60% 52W Range95.58 - 303.79 Perf YTD12.13%
Dividend- P/FCF37.07 EPS past 5Y17.90% ROI8.60% 52W High-7.77% Beta1.11
Dividend %- Quick Ratio1.20 Sales past 5Y16.50% Gross Margin36.70% 52W Low193.14% ATR9.34
Employees18400 Current Ratio1.40 Sales Q/Q14.50% Oper. Margin14.80% RSI (14)51.63 Volatility3.41% 3.13%
OptionableYes Debt/Eq0.94 EPS Q/Q73.20% Profit Margin12.50% Rel Volume0.96 Prev Close288.22
ShortableYes LT Debt/Eq0.91 EarningsFeb 17 BMO Payout0.00% Avg Volume308.20K Price280.18
Recom1.90 SMA200.69% SMA505.11% SMA20025.36% Volume295,122 Change-2.79%
Dec-16-20Downgrade Citigroup Buy → Neutral $270 → $250
Sep-10-20Upgrade Jefferies Hold → Buy $254
Jul-01-20Upgrade BofA Securities Neutral → Buy $192
May-13-20Upgrade UBS Neutral → Buy $177 → $200
Apr-21-20Downgrade Jefferies Buy → Hold $139
Mar-27-20Upgrade Morgan Stanley Equal-Weight → Overweight $152
Mar-02-20Initiated Deutsche Bank Buy $190
Feb-18-20Upgrade Wolfe Research Peer Perform → Outperform
Jan-10-20Upgrade Goldman Neutral → Buy $143 → $179
Jan-08-20Initiated Wells Fargo Overweight $180
Jan-07-20Initiated Citigroup Buy $185
Oct-18-19Downgrade BofA/Merrill Buy → Neutral $150
Jun-10-19Initiated SVB Leerink Outperform $155
Apr-30-19Resumed Evercore ISI Outperform $160
Dec-14-18Initiated Deutsche Bank Buy
Oct-09-18Initiated UBS Neutral
Aug-23-18Upgrade Raymond James Mkt Perform → Outperform
Jul-17-18Upgrade RBC Capital Mkts Sector Perform → Outperform
Jun-15-18Upgrade KeyBanc Capital Mkts Sector Weight → Overweight
Feb-14-18Upgrade SunTrust Hold → Buy
Feb-25-21 08:00AM  
Feb-24-21 05:20AM  
Feb-18-21 01:15PM  
08:52AM  
Feb-17-21 04:00PM  
07:35AM  
07:08AM  
07:06AM  
Feb-10-21 12:31PM  
Jan-29-21 12:10PM  
Jan-28-21 08:00AM  
Jan-21-21 11:57PM  
Jan-20-21 08:30AM  
Jan-15-21 12:57PM  
Jan-14-21 08:00AM  
Jan-11-21 08:00AM  
Jan-06-21 04:03PM  
Jan-04-21 07:00AM  
Dec-25-20 02:44PM  
Dec-23-20 12:34AM  
Dec-21-20 01:42AM  
Dec-16-20 12:16PM  
Dec-09-20 08:00AM  
Nov-27-20 12:43AM  
Nov-20-20 03:07PM  
Nov-19-20 12:45PM  
Nov-12-20 08:00AM  
Nov-09-20 08:30AM  
Nov-05-20 09:15AM  
Nov-03-20 12:45PM  
Nov-01-20 08:20AM  
Oct-30-20 04:31AM  
Oct-29-20 09:00PM  
07:00AM  
Oct-28-20 12:26PM  
Oct-27-20 06:03PM  
Oct-26-20 06:53AM  
Oct-22-20 12:34PM  
12:10PM  
Oct-18-20 09:00PM  
Oct-17-20 12:19AM  
Oct-16-20 09:15AM  
Oct-13-20 08:30AM  
Oct-07-20 12:45PM  
Sep-26-20 09:51AM  
Sep-23-20 11:49AM  
Sep-21-20 02:52PM  
Sep-15-20 04:03PM  
03:11PM  
02:25PM  
11:36AM  
Sep-13-20 08:00PM  
08:00PM  
Sep-09-20 09:35AM  
Sep-08-20 08:30AM  
Aug-31-20 08:59AM  
Aug-28-20 11:20AM  
Aug-07-20 02:00AM  
Aug-05-20 05:00PM  
09:05AM  
07:53AM  
07:21AM  
07:00AM  
Aug-04-20 05:53PM  
05:39PM  
09:41AM  
09:07AM  
Jul-31-20 12:32PM  
Jul-29-20 12:33PM  
Jul-24-20 07:39PM  
Jul-22-20 09:19AM  
Jul-20-20 12:10PM  
Jul-15-20 04:42PM  
Jul-14-20 08:30AM  
Jul-13-20 05:03PM  
Jul-09-20 03:24PM  
Jun-15-20 09:59AM  
Jun-11-20 10:05AM  
09:02AM  
Jun-10-20 10:25AM  
Jun-03-20 02:46AM  
Jun-02-20 08:00AM  
07:58AM  
Jun-01-20 08:00AM  
May-30-20 10:54PM  
11:42AM  
May-28-20 11:00AM  
May-21-20 07:13AM  
May-09-20 09:12AM  
May-08-20 12:31AM  
May-07-20 08:25AM  
07:00AM  
Apr-30-20 12:34PM  
Apr-29-20 12:08PM  
Apr-20-20 03:24PM  
Apr-19-20 03:54PM  
Apr-16-20 08:40AM  
08:30AM  
Mar-30-20 08:30AM  
Mar-25-20 06:26AM  
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains primarily purpose-bred rats and mice for use by researchers. It also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification of a druggable target through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as bioanalysis, drug metabolism, pharmacokinetics, safety pharmacology, toxicology, and pathology services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile biopharmaceuticals, and consumer products. It also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company has a strategic partnership with PathoQuest SAS to establish a sequencing based testing laboratory; and an agreement with Algernon Pharmaceuticals Inc. for preclinical studies of AP-188 (N,N-Dimethyltryptamine) for the company's stroke clinical research program. Charles River Laboratories International, Inc. is based in Wilmington, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
FOSTER JAMES CChairman, President and CEOFeb 24Option Exercise88.0524,0092,113,992245,160Feb 25 04:23 PM
FOSTER JAMES CChairman, President and CEOFeb 24Sale284.7524,0096,836,607221,151Feb 25 04:23 PM
CHUBB STEPHEN DDirectorFeb 23Option Exercise52.293,530184,58441,187Feb 24 11:02 AM
FOSTER JAMES CChairman, President and CEOFeb 23Option Exercise109.3420,2952,219,055243,656Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 23Sale279.8020,2955,678,578223,361Feb 24 11:10 AM
CHUBB STEPHEN DDirectorFeb 23Sale281.66658185,33040,529Feb 24 11:02 AM
FOSTER JAMES CChairman, President and CEOFeb 22Option Exercise144.6717,4362,522,466244,605Feb 24 11:10 AM
FOSTER JAMES CChairman, President and CEOFeb 22Sale282.9817,4364,934,118227,169Feb 24 11:10 AM
Girshick BirgitCorporate Executive VPFeb 19Option Exercise73.701,675123,44831,680Feb 23 11:41 AM
Girshick BirgitCorporate Executive VPFeb 19Sale293.921,675492,31130,005Feb 23 11:41 AM
Knell Michael GunnarCSVP&Chief Accounting OfficerFeb 19Sale290.99410119,3054,198Feb 23 11:32 AM
Smith David RossCorporate Executive VP & CFOFeb 19Sale290.638,6562,515,6860Feb 23 11:16 AM
FOSTER JAMES CChairman, President and CEOFeb 11Sale285.0230,0008,550,556227,169Feb 16 11:58 AM
Smith David RossCorporate Executive VP & CFOJan 04Sale248.765,0001,243,78815,767Jan 05 05:21 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Option Exercise123.736,739833,84118,095Nov 05 11:46 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopNov 04Sale250.286,7391,686,62711,356Nov 05 11:46 AM
Barbo William DCorporate Executive VP & CCONov 03Sale236.292,150508,0159,821Nov 05 03:51 PM
WALLMAN RICHARD FDirectorNov 02Buy233.246,0501,411,1046,050Nov 03 01:21 PM
WALLMAN RICHARD FDirectorNov 02Buy232.961,150267,90231,715Nov 03 01:21 PM
FOSTER JAMES CChairman, President and CEONov 02Sale232.3822,0005,112,267186,777Nov 03 04:05 PM
MASSARO GEORGEDirectorSep 14Sale219.911,943427,2849,441Sep 15 05:47 PM
Girshick BirgitCorporate Executive VPAug 20Sale213.51933199,20522,852Aug 21 10:48 AM
CHUBB STEPHEN DDirectorAug 18Sale217.651,000217,65137,657Aug 19 02:48 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Option Exercise111.413,441383,3535,855Aug 10 03:20 PM
Smith David RossCorporate Executive VP & CFOAug 07Option Exercise144.673,304477,99024,071Aug 10 04:18 PM
Smith David RossCorporate Executive VP & CFOAug 07Sale216.543,304715,44420,767Aug 10 04:18 PM
Knell Michael GunnarCSVP&Chief Accounting OfficerAug 07Sale216.603,456748,5552,399Aug 10 03:20 PM
Kochevar Deborah TurnerDirectorAug 07Sale216.242,319501,4676,728Aug 11 10:39 AM
FOSTER JAMES CChairman, President and CEOAug 07Sale217.4924,0005,219,771210,777Aug 10 04:25 PM
MASSARO GEORGEDirectorMay 22Sale173.40941163,16811,884May 26 02:37 PM
BERTOLINI ROBERT JDirectorMay 20Option Exercise52.293,530184,58432,664May 21 11:36 AM
BERTOLINI ROBERT JDirectorMay 20Sale174.583,530616,26329,134May 21 11:36 AM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 18Sale174.6535061,1289,637May 19 04:18 PM
FOSTER JAMES CChairman, President and CEOMay 18Sale175.0017,4353,051,125229,894May 19 04:14 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Option Exercise80.486,350511,04525,405May 19 04:18 PM
LaPlume Joseph WEVP, Corp Strategy & DevelopMay 15Sale168.2615,4182,594,1709,987May 19 04:18 PM
Girshick BirgitCorporate Executive VPMay 12Sale165.74780129,27721,837May 13 08:18 AM
FOSTER JAMES CChairman, President and CEOMay 11Sale162.5317,4462,835,433249,329May 13 11:02 AM
Smith David RossCorporate Executive VP & CFOMay 07Sale150.001,884282,60018,591May 08 10:48 AM
Barbo William DCorporate Executive VP & CCOMar 05Option Exercise102.5612,4671,278,67730,201Mar 06 03:50 PM
Barbo William DCorporate Executive VP & CCOMar 05Sale164.3513,9662,295,30016,235Mar 06 03:50 PM
CHUBB STEPHEN DDirectorFeb 27Option Exercise55.177,170395,57242,005Feb 28 10:28 AM
CHUBB STEPHEN DDirectorFeb 27Sale160.892,464396,43739,541Feb 28 10:28 AM
FOSTER JAMES CChairman, President and CEOFeb 26Option Exercise73.7025,1241,851,639311,899Feb 27 02:45 PM
Smith David RossCorporate Executive VP & CFOFeb 26Option Exercise73.704,188308,65624,663Feb 27 02:48 PM
Smith David RossCorporate Executive VP & CFOFeb 26Sale162.264,188679,53520,475Feb 27 02:48 PM
FOSTER JAMES CChairman, President and CEOFeb 26Sale162.2525,1244,076,411286,775Feb 27 02:45 PM